Achieve Life Sciences, Inc. Interest Expense
Achieve Life Sciences, Inc. (ACHV) reported Interest Expense of $366.00 thousand for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2024-11-07
- Achieve Life Sciences, Inc. interest expense for the quarter ending 2024-09-30 was $366.00K, a 53.14% decline year-over-year.
- Achieve Life Sciences, Inc. interest expense for the quarter ending 2024-06-30 was $804.00K, a 12.92% increase year-over-year.
- Achieve Life Sciences, Inc. interest expense for the quarter ending 2024-03-31 was $813.00K, a 41.88% increase year-over-year.
- Achieve Life Sciences, Inc. interest expense for the quarter ending 2023-12-31 was $787.00K, a 43.88% increase year-over-year.
- Achieve Life Sciences, Inc. interest expense for fiscal 2023 was $2.85M, a 59.47% increase from fiscal 2022.
- Achieve Life Sciences, Inc. interest expense for fiscal 2022 was $1.79M.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2024-09-30 | $366.00K 10-Q · filed 2024-11-07 | $1.17M derived: sum of 2 quarters · filed 2024-11-07 | $1.98M 10-Q · filed 2024-11-07 | $2.77M derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | $804.00K 10-Q · filed 2024-08-13 | $1.62M 10-Q · filed 2024-08-13 | $2.40M derived: sum of 3 quarters · filed 2024-08-13 | $3.19M derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-03-31 | $813.00K 10-Q · filed 2024-05-09 | $1.60M derived: sum of 2 quarters · filed 2024-05-09 | $2.38M derived: sum of 3 quarters · filed 2024-11-07 | $3.09M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-12-31 | $787.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $1.57M derived: sum of 2 quarters · filed 2024-11-07 | $2.28M derived: sum of 3 quarters · filed 2024-11-07 | $2.85M 10-K · filed 2024-03-28 |
| 2023-09-30 | $781.00K 10-Q · filed 2024-11-07 | $1.49M derived: sum of 2 quarters · filed 2024-11-07 | $2.07M 10-Q · filed 2024-11-07 | $2.61M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $712.00K 10-Q · filed 2024-08-13 | $1.28M 10-Q · filed 2024-08-13 | $1.83M derived: sum of 3 quarters · filed 2024-08-13 | $2.31M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | $573.00K 10-Q · filed 2024-05-09 | $1.12M derived: sum of 2 quarters · filed 2024-05-09 | $1.60M derived: sum of 3 quarters · filed 2024-05-09 | $2.00M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $547.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $1.03M derived: sum of 2 quarters · filed 2024-03-28 | $1.43M derived: sum of 3 quarters · filed 2024-03-28 | $1.79M 10-K · filed 2024-03-28 |
| 2022-09-30 | $481.00K 10-Q · filed 2023-11-09 | $885.00K derived: sum of 2 quarters · filed 2023-11-09 | $1.24M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | $404.00K 10-Q · filed 2023-08-14 | $761.00K 10-Q · filed 2023-08-14 | ||
| 2022-03-31 | $357.00K 10-Q · filed 2023-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |